Alterity Therapeutics said that it has launched a phase 2 clinical trial of its lead candidate ATH434 in patients with multiple system atrophy (MSA). According to the Australian biotech company, the mid-stage clinical trial is now open for patient enrolment in New Zealand. Alterity Therapeutics believes that ATH434 lowers the toxic accumulation of α-synuclein, which […]
Connecticut-based Biohaven Pharmaceutical has received a significant regulatory boost, with the US FDA granting orphan drug designation for its investigational drug verdiperstat for treating multiple system atrophy (MSA). This rare and debilitating neurodegenerative disease has long been a target for pharmaceutical companies seeking breakthroughs in treatment, and verdiperstat’s designation underscores its potential as a game-changer […]
In a significant milestone, Prana Biotechnology, an Australian biotech company, has obtained Orphan Drug designation from the FDA for PBT434, its lead molecule aimed at treating Multiple System Atrophy (MSA), a rare and degenerative neurological disease. This designation offers Prana Biotechnology substantial regulatory advantages, such as seven years of market exclusivity and access to tax […]